14 CLINICAL STUDIES
The long-term effects of XENICAL on morbidity and mortality associated with obesity have not been established.
The effects of XENICAL on weight loss, weight maintenance, and weight regain and on a number of comorbidities (e.g., type 2 diabetes, lipids, blood pressure) were assessed in the 4-year XENDOS study and in seven long-term (1- to 2-years duration) multicenter, double-blind, placebo-controlled clinical trials. During the first year of therapy, the studies of 2-year duration assessed weight loss and weight maintenance. During the second year of therapy, some studies assessed continued weight loss and weight maintenance and others assessed the effect of XENICAL on weight regain. These studies included over 2800 patients treated with XENICAL and 1400 patients treated with placebo (age range 17-78 years, 80.2% women, 91.0% Caucasians, 5.7% Blacks, 2.3% Hispanics, 0.9% Other). The majority of these patients had obesity-related risk factors and comorbidities. In the XENDOS study, which included 3304 patients (age range 30-58 years, 55% women, 99% Caucasians, 1% other), the time to onset of type 2 diabetes was assessed in addition to weight management. In all these studies, treatment with XENICAL and placebo designates treatment with XENICAL plus diet and placebo plus diet, respectively.
During the weight loss and weight maintenance period, a well-balanced, reduced-calorie diet that was intended to result in an approximate 20% decrease in caloric intake and provide 30% of calories from fat was recommended to all patients. In addition, all patients were offered nutritional counseling.
14.1 One-year Results: Weight Loss, Weight Maintenance, and Risk Factors
14.1 Weight Reduction and Long-term Maintenance Trials in Adults with Obesity or Overweight
Overview of Clinical Trials in Adults
The effects of XENICAL 120 mg administered orally three times a day on weight reduction and long-term maintenance of body weight in conjunction with a reduced calorie diet that provided approximately 30% of calories from fat were assessed in seven multicenter, double-blind, placebo-controlled clinical trials of 1- to 2-years duration, and in a 4-year trial. The seven trials included 1,466 patients treated with placebo, 1,913 patients treated with XENICAL 120 mg orally three times a day, and 809 patients treated with unapproved dosages of XENICAL. Patients were 17 to 78 years of age; 80% were female, 91% White, 6% Black or African American, 2% were of Hispanic or Latino ethnicity, and 1% were of other races. Six of the trials enrolled patients without type 2 diabetes mellitus (Trials 1-6) and one of the trials enrolled a population of patients with type 2 diabetes mellitus (Trial 7). The 4-year trial (Trial 8) included 3,304 patients; age range 30 to 58 years; 55% were female; 99% were White and 1% other races. This trial included a subset of patients with abnormal glucose at baseline.
Effect of XENICAL on Body Weight After 1 Year of Treatment
Pooled data from five clinical trials indicated that the overall mean weight loss from randomization to the end of 1 year of treatment in the intent-to-treat population was 13.4 lbs in the patients treated with XENICAL and 5.8 lbs in the placebo-treated patients. After 1 year of treatment, the mean percent weight loss difference between XENICAL-treated patients and placebo-treated patients was 3%. One thousand seventy two (69%) patients treated with XENICAL and 701 (63%) patients treated with placebo completed 1 year of treatment. Of the patients who completed 1 year of treatment, 57% of the patients treated with XENICAL (120 mg three times a day) and 31% of the placebo-treated patients lost at least 5% of their baseline body weight.
A total of 2,680 obese patients were randomly assigned to receive either placebo (n = 1,119) or XENICAL 120 mg orally three times a day (n = 1,561) for at least one year in five clinical trials. Baseline mean body weight was approximately 100 kg in the pool of Trials 1-5. A total of 1,072 (69%) patients treated with XENICAL and 701 (63%) patients treated with placebo completed 1 year of treatment. After 1 year of treatment, the mean percent weight loss difference between XENICAL-treated patients and placebo-treated patients was 3%. Greater proportions of patients treated with XENICAL achieved 5% and 10% weight loss than those treated with placebo as shown in Table 5.
Table 5 Percentage of Patients Losing ≥ 5% and ≥ 10% of Body Weight from Randomization After 1 Year of Treatmenta
Trial Number | ≥5% Weight Loss | ≥10% Weight Loss
Placebo | N | XENICAL | N | p-value | Placebo | N | XENICAL | N | p-value
1 | 21.3% | 108 | 35.5% | 110 | 0.021 | 6.5% | 108 | 16.4% | 110 | 0.022
2 | 27.4% | 340 | 54.8% | 343 | <0.001 | 8.2% | 340 | 24.8% | 343 | <0.001
3 | 26.3% | 236 | 50.6% | 241 | <0.001 | 11.9% | 236 | 22.8% | 241 | 0.02
4b | 16.0% | 212 | 37.1% | 210 | <0.001 | 3.8% | 212 | 19.5% | 210 | <0.001
5 | 22.4% | 223 | 42.6% | 657 | <0.001 | 9.9% | 223 | 17.7% | 657 | 0.006
a modified intent to treat – last observation carried forward (MITT-LOCF)
b All trials, with the exception of Trial 4, were conducted at centers specialized in treating obesity and complications of obesity. Trial 4 was conducted with primary care physicians.
Effect of XENICAL on Anthropometry and Cardiometabolic Parameters
The changes in anthropometry and cardiometabolic parameters at the end of the 1-year treatment period in the all trials population (Trials 1-5) are presented in Table 6.
Table 6 Mean Changes in Anthropometry and Cardiometabolic Parameters from Randomization Following 1 Year of Treatmenta,bin the All Trials Population of Clinical Trials 1 – 5
Parameter | Placebo | XENICAL
Total Cholesterol | +5.0% | -2.0%
LDL-Cholesterol | +5.0% | -4.0%
HDL-Cholesterol | +12.8% | +9.3%
Triglycerides | +2.9% | +1.34%
Systolic Blood Pressure (mmHg) | +0.58 | -1.01
Diastolic Blood Pressure (mmHg) | +0.46 | -1.19
Waist Circumference (cm) | -4.04 | -6.45
a modified intent to treat – last observation carried forward (MITT-LOCF)
b Change from baseline at 1 year of treatment.
Effect of XENICAL on Body Weight After 2 Years of Treatment
The treatment effects of XENICAL were examined for 2 years in four trials (Trials 2-5). The 2-year analysis population included a total of 1,122 patients who were randomly assigned to receive either placebo (n = 516) or XENICAL (n = 606). Patients were included only if they had been randomly assigned to receive the same treatment for both years – either placebo, or XENICAL 120 mg orally three times a day– and only if they had completed the first year of treatment. At the end of year 1, the patients’ diets were reviewed and changed where necessary. The diet prescribed in the second year was designed to maintain a patient’s current weight. The mean baseline body weight was 99 kg.
The proportion of patients (pooled from four clinical trials) who completed 1 year of treatment and went on to complete a second year of therapy was 74% for XENICAL (n = 450) and 76% for placebo (n = 392). Pooled data from four clinical trials indicate that the mean weight loss difference between XENICAL 120 mg three times a day and placebo treatment groups at year 2 in those patients who completed 1 year of treatment (LOCF) was 3% The percentages of patients achieving a ≥5% and ≥10% weight loss after 2 years are shown in Table 7.
Table 7 Percentage of Patients Losing ≥ 5% and ≥ 10% of Body Weight from Randomization After 2 Years of Treatmenta
Trial Number | ≥5% Weight Loss | ≥10% Weight Loss
Placebo | N | XENICAL | N | p-value | Placebo | N | XENICAL | N | p-value
2 | 23.6% | 123 | 45.1% | 133 | <0.001 | 6.5% | 123 | 24.8% | 133 | <0.001
3 | 27.2% | 158 | 43.3% | 178 | 0.002 | 9.5% | 158 | 18.0% | 178 | 0.025
4b | 15.0% | 113 | 25.0% | 148 | 0.049 | 3.5% | 113 | 16.9% | 148 | 0.001
5 | 27.9% | 122 | 34.0% | 147 | 0.279 | 11.5% | 122 | 17.7% | 147 | 0.154
a modified intent to treat – last observation carried forward (MITT-LOCF)
b All trials, with the exception of Trial 4, were conducted at centers specializing in treating obesity or complications of obesity. Trial 4 was conducted with primary care physicians.
The relative differences in anthropometry and cardiometabolic parameters between treatment with XENICAL and placebo were similar to the results following 1 year of therapy for total cholesterol, LDL-cholesterol, triglycerides, diastolic blood pressure, and waist circumference. The relative differences between treatment groups for HDL cholesterol and systolic blood pressure were less than that observed in the year one results.
Effect of XENICAL on Body Weight After 4 Years of Treatment
In the 4-year double-blind, placebo-controlled trial (Trial 8), the effects of XENICAL on body weight were compared to placebo in 3,304 patients with obesity who had either normal or impaired blood glucose tolerance at baseline. Mean baseline body weight was 110.5 kg and mean BMI was 37.4 kg/m2. A total of 564 patients (34%) of the 1,655 patients, who were randomized to the placebo group, and 850 patients (52%) of the 1,649 patients, who were randomized to the XENICAL group, completed the 4-year study.
At the end of the study, the mean percent weight loss in the placebo group was -2.75% compared with -5.17% in the XENICAL group (p<0.001). Figure 2 presents mean percent change from baseline body weight observed for patients completing each study visit.
Forty-five percent of the placebo patients and 73% of the XENICAL patients lost ≥5% of their baseline body weight, and 21% of the placebo patients and 41% of the XENICAL patients lost ≥10% of their baseline body weight following the first year of treatment. Following 4 years of treatment, 28% of the placebo patients and 45% of the XENICAL patients lost ≥5% of their baseline body weight and 10% of the placebo patients and 21% of the XENICAL patients lost ≥10% of their baseline body weight. After 4 years of treatment, the mean percent difference in weight loss between XENICAL-treated patients and placebo was 2.5%.
Figure 2 Mean Change from Baseline Body Weight (%) Over Time a
a Observed values for patients completing each scheduled visit.
Effect of XENICAL on Body Weight in Adults with Type 2 Diabetes Mellitus and Obesity or Overweight
A 1-year double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus with obesity or overweight (n = 321) stabilized on sulfonylureas was conducted (Trial 7). Mean baseline body weight was 99.7 kg and mean BMI was 34.3 kg/m2. Following 1 year of treatment, the mean change in body weight was 6.19 kg with XENICAL and 4.31 kg with placebo (p≤0.05). Thirty percent (30%) of patients treated with XENICAL achieved at least a 5% or greater reduction in body weight from randomization compared to 13% of the placebo-treated patients (p<0.001).
The changes in HbA1c and cardiometabolic parameters at the end of the 1-year treatment period in Trial 7 are presented in Table 8.
Table 8 Mean Changes in HbA1c and Cardiometabolic Parameters from Randomization Following 1 Year of Treatmenta
Parameter | Placebo | XENICAL
Total Cholesterol | +9.0 | -0.9
LDL-Cholesterol | +9.5 | -3.0
HDL-Cholesterol | +8.6 | +6.5
Triglycerides | +16.2 | +2.5
HbA1c (%) | +0.28 | -0.18
Systolic Blood Pressure (mmHg) | +4.3 | +0.6
Diastolic Blood Pressure (mmHg) | -0.5 | -0.5
a modified intent to treat – last observation carried forward (MITT-LOCF)
14.2 Weight Reduction and Long-term Maintenance Trial in Pediatric Patients Aged 12 Years and Older with Obesity
The effects of XENICAL on weight reduction and long-term maintenance were assessed in a 54-week multicenter, double-blind, placebo-controlled study in 539 pediatric patients aged 12 years and older with obesity (357 receiving XENICAL 120 mg three times a day, 182 receiving placebo). A similar percentage of patients in each treatment group (placebo 64%, XENICAL 65%) completed the study. The mean baseline BMI was 36 kg/m2 in both treatment groups, and the mean baseline body weight was 98 kg among XENICAL-treated patients and 95 kg for placebo-treated patients. All study participants had a baseline BMI that was 2 units greater than the US weighted mean for the 95th percentile based on age and sex. The primary endpoint was percent change from baseline BMI. The mean age was 13.5 years. Most of the patients were White (XENICAL 75%, placebo 78%), Black or African American (XENICAL 19%, placebo 14%) and females (XENICAL 65%, placebo 71%).
During the study, all patients were instructed to take a multivitamin containing fat-soluble vitamins at least 2 hours before or after ingestion of XENICAL. Patients were instructed to maintain a reduced-calorie diet that provided 30% of calories from fat, 50% of calories from carbohydrate, and 20% of calories as protein. In addition, all patients were enrolled in a behavior modification program and offered counseling on physical activity.
At week 54, the least squared mean change from baseline in BMI was -0.55 kg/m2 in XENICAL-treated patients and +0.31 kg/m2 in placebo-treated patients (p=0.001).
The percentages of patients achieving ≥5% and ≥10% weightreduction lossin afterBMI 1and yearbody inweight fiveafter large52 multicenterweeks studiesof treatment for the intent-to-treat populationspopulation are presented in Table 6 9.
Table 6 Percentage of Patients Losing ≥5% and ≥10% of Body Weight From Randomization After 1-Year Treatment
Table 9 Percentages of Patients with ≥5% and ≥10% Decrease in Body Mass Index and Body Weight After 1 Year of Treatmenta
Study No. | Intent-to-Treat Population
≥5% Weight Loss | ≥10% Weight Loss
| ≥5% Decrease | ≥10% Decrease
XENICAL | n | Placebo | n | p-value | XENICAL | n | Placebo | n | p-value
Placebo | N | XENICAL | N | Placebo | N | XENICAL | N
The diet utilized during year 1 was a reduced-calorie diet.
14119B | 35.5% | 110 | 21.3% | 108 | 0.021 | 16.4% | 110 | 6.5% | 108 | 0.022
14119C | 54.8% | 343 | 27.4% | 340 | <0.001 | 24.8% | 343 | 8.2% | 340 | <0.001
14149 | 50.6% | 241 | 26.3% | 236 | <0.001 | 22.8% | 241 | 11.9% | 236 | 0.02
14161 | 37.1% | 210 | 16.0% | 212 | <0.001 | 19.5% | 210 | 3.8% | 212 | <0.001
14185 | 42.6% | 657 | 22.4% | 223 | <0.001 | 17.7% | 657 | 9.9% | 223 | 0.006
The relative changes in risk factors associated with obesity following 1 year of therapy with XENICAL and placebo are presented for the population as a whole and for the population with abnormal values at randomization.
Population as a Whole
The changes in metabolic, cardiovascular and anthropometric risk factors associated with obesity based on pooled data for five clinical studies, regardless of the patient's risk factor status at randomization, are presented in Table 7 . One year of therapy with XENICAL resulted in relative improvement in several risk factors.
Table 7 Mean Change in Risk Factors From Randomization Following 1-Year Treatment Population as a Whole
Risk Factor | XENICAL 120 mg | Placebo
Metabolic: | |
Total Cholesterol | -2.0% | +5.0%
LDL-Cholesterol | -4.0% | +5.0%
HDL-Cholesterol | +9.3% | +12.8%
LDL/HDL | -0.37 | -0.20
Triglycerides | +1.34% | +2.9%
Fasting Glucose, mmol/L | -0.04 | +0.0
Fasting Insulin, pmol/L | -6.7 | +5.2
Cardiovascular: | |
Systolic Blood Pressure, mm Hg | -1.01 | +0.58
Diastolic Blood Pressure, mm Hg | -1.19 | +0.46
Anthropometric: | |
Waist Circumference, cm | -6.45 | -4.04
Hip Circumference, cm | -5.31 | -2.96
Population With Abnormal Risk Factors at Randomization
The changes from randomization following 1-year treatment in the population with abnormal lipid levels (LDL ≥130 mg/dL, LDL/HDL ≥3.5, HDL <35 mg/dL) were greater for XENICAL compared to placebo with respect to LDL-cholesterol (-7.83% vs +1.14%) and the LDL/HDL ratio (-0.64 vs -0.46). HDL increased in the placebo group by 20.1% and in the XENICAL group by 18.8%. In the population with abnormal blood pressure at baseline (systolic BP ≥140 mm Hg), the change in SBP from randomization to 1 year was greater for XENICAL (-10.89 mm Hg) than placebo (-5.07 mm Hg). For patients with a diastolic blood pressure ≥90 mm Hg, XENICAL patients decreased by -7.9 mm Hg while the placebo patients decreased by -5.5 mm Hg. Fasting insulin decreased more for XENICAL than placebo (-39 vs -16 pmol/L) from randomization to 1 year in the population with abnormal baseline values (≥120 pmol/L). A greater reduction in waist circumference for XENICAL vs placebo (-7.29 vs -4.53 cm) was observed in the population with abnormal baseline values (≥100 cm).
14.2 Effect on Weight Regain
Three studies were designed to evaluate the effects of XENICAL compared to placebo in reducing weight regain after a previous weight loss achieved following either diet alone (one study, 14302) or prior treatment with XENICAL (two studies, 14119C and 14185). The diet utilized during the 1-year weight regain portion of the studies was a weight-maintenance diet, rather than a weight-loss diet, and patients received less nutritional counseling than patients in weight-loss studies. For studies 14119C and 14185, patients' previous weight loss was due to 1 year of treatment with XENICAL in conjunction with a mildly hypocaloric diet. Study 14302 was conducted to evaluate the effects of 1 year of treatment with XENICAL on weight regain in patients who had lost 8% or more of their body weight in the previous 6 months on diet alone.
In study 14119C, patients treated with placebo regained 52% of the weight they had previously lost while the patients treated with XENICAL regained 26% of the weight they had previously lost (p<0.001). In study 14185, patients treated with placebo regained 63% of the weight they had previously lost while the patients treated with XENICAL regained 35% of the weight they had lost (p<0.001). In study 14302, patients treated with placebo regained 53% of the weight they had previously lost while the patients treated with XENICAL regained 32% of the weight that they had lost (p<0.001).
14.3 Two-year Results: Long-term Weight Control and Risk Factors
The treatment effects of XENICAL were examined for 2 years in four of the five 1-year weight management clinical studies previously discussed (see Table 6 ). At the end of year 1, the patients' diets were reviewed and changed where necessary. The diet prescribed in the second year was designed to maintain patient's current weight. XENICAL was shown to be more effective than placebo in long-term weight control in four large, multicenter, 2-year double-blind, placebo-controlled studies.
Pooled data from four clinical studies indicate that 74% of all patients treated with 120 mg three times a day of XENICAL and 76% of patients treated with placebo completed 2 years of the same therapy. Pooled data from four clinical studies indicate that the mean weight loss difference between XENICAL 120 mg three times a day and placebo treatment groups at year 2 in those patients who completed 1 year of treatment (ITT LOCF) was 3%. In the same studies cited in the One-year Results (see Table 6 ), the percentages of patients achieving a ≥5% and ≥10% weight loss after 2 years are shown in Table 8 .
Table 8 Percentage of Patients Losing ≥5% and ≥10% of Body Weight From Randomization After 2-Year Treatment
Study No. | Intent-to-Treat Population
≥5% Weight Loss | ≥10% Weight Loss
XENICAL | n | Placebo | n | p-value | XENICAL | n | Placebo | n | p-value
The diet utilized during year 2 was designed for weight maintenance and not weight loss.
14119C | 45.1% | 133 | 23.6% | 123 | <0.001 | 24.8% | 133 | 6.5% | 123 | <0.001
14149 | 43.3% | 178 | 27.2% | 158 | 0.002 | 18.0% | 178 | 9.5% | 158 | 0.025
14161 | 25.0% | 148 | 15.0% | 113 | 0.049 | 16.9% | 148 | 3.5% | 113 | 0.001
14185 | 34.0% | 147 | 27.9% | 122 | 0.279 | 17.7% | 147 | 11.5% | 122 | 0.154
The relative changes in risk factors associated with obesity following 2 years of therapy were also assessed in the population as a whole and the population with abnormal risk factors at randomization.
Population as a Whole
The relative differences in risk factors between treatment with XENICAL and placebo were similar to the results following 1 year of therapy for total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, fasting glucose, fasting insulin, diastolic blood pressure, waist circumference, and hip circumference. The relative differences between treatment groups for HDL cholesterol and systolic blood pressure were less than that observed in the year one results.
Population With Abnormal Risk Factors at Randomization
The relative differences in risk factors between treatment with XENICAL and placebo were similar to the results following 1 year of therapy for LDL- and HDL-cholesterol, triglycerides, fasting insulin, diastolic blood pressure, and waist circumference. The relative differences between treatment groups for LDL/HDL ratio and isolated systolic blood pressure were less than that observed in the year one results.
14.4 Four-year Results: Long-term Weight Control and Risk Factors
In the 4-year double-blind, placebo-controlled XENDOS study, the effects of XENICAL in delaying the onset of type 2 diabetes and on body weight were compared to placebo in 3304 obese patients who had either normal or impaired glucose tolerance at baseline. Thirty-four percent of the 1655 patients who were randomized to the placebo group and 52% of the 1649 patients who were randomized to the XENICAL group completed the 4-year study.
At the end of the study, the mean percent weight loss in the placebo group was -2.75% compared with -5.17% in the XENICAL group (p<0.001) (see Figure 2 ). Forty-five percent of the placebo patients and 73% of the XENICAL patients lost ≥5% of their baseline body weight, and 21% of the placebo patients and 41% of the XENICAL patients lost ≥10% of their baseline body weight following the first year of treatment. Following 4 years of treatment, 28% of the placebo patients and 45% of the XENICAL patients lost ≥5% of their baseline body weight and 10% of the placebo patients and 21% of the XENICAL patients lost ≥10% of their baseline body weight. After 4 years of treatment, the mean % difference in weight loss between XENICAL treated patients and placebo was 2.5%.
Figure 2 Mean Change from Baseline Body Weight (Kgs) Over Time*
*ITT LOCF study population
The relative changes from baseline in risk factors associated with obesity following 4 years of therapy were assessed in the XENDOS study population (see Table 9 ).
Table 9 Mean Change in Risk Factors From Randomization Following 4-Years Treatment
Risk Factor | XENICAL 120 mg | Placebo
Metabolic: | |
Total Cholesterol | -7.02% | -2.03%
LDL-Cholesterol | -11.66% | -3.85%
HDL-Cholesterol | +5.92% | +7.01%
LDL/HDL | -0.53 | -0.33
Triglycerides | +3.64% | +1.30
Fasting Glucose, mmol/L | +0.12 | +0.23
Fasting Insulin, pmol/L | -24.93 | -15.71
Cardiovascular: | |
Systolic Blood Pressure, mm Hg | -4.12 | -2.60
Diastolic Blood Pressure, mm Hg | -1.93 | -0.87
Anthropometric: | |
Waist Circumference, cm | -5.78 | -3.99
Onset of Type 2 Diabetes in Obese Patients
In the XENDOS trial, in the overall population, XENICAL delayed the onset of type 2 diabetes such that at the end of four years of treatment the cumulative incidence rate of diabetes was 8.3% for the placebo group compared to 5.5% for the XENICAL group, p=0.01 (see Table 10 ). This finding was driven by a statistically-significant reduction in the incidence of developing type 2 diabetes in those patients who had impaired glucose tolerance at baseline ( Table 10 and Figure 3 ). XENICAL did not reduce the risk for the development of diabetes in patients with normal glucose tolerance at baseline.
The effect of XENICAL to delay the onset of type 2 diabetes in obese patients with IGT is presumably due to weight loss, and not to any independent effects of the drug on glucose or insulin metabolism. The effect of XENICAL on weight loss is adjunctive to diet and exercise.
Table 10 Incidence Rate of Diabetes at Year 4 by OGTT Status at Baseline
OGTT at Baseline | Normal | Impaired | All
Treatment | Placebo | XENICAL | Placebo | XENICAL | Placebo | XENICAL
Number of patients | 1148 | 1235 | 324 | 337 | 1472 | 1572
# pts developing diabetes | 16 | 21 | 62 | 48 | 78 | 69
Life table rate | 2.1% | 1.7% | 27.2% | 18.7% | 8.3% | 5.5%
Observed percent | 1.4% | 1.7% | 19.1% | 14.2% | 5.3% | 4.4%
Absolute risk reduction | | |
Life table | 0.4% | 8.5% | 2.8%
Observed | -0.3% | 4.9% | 0.9%
Relative risk reduction | 8% | 42% | 34%
p-value | 0.79 | <0.01 | 0.01
Figure 3 Percentage of Patients Without Diabetes Over Time
14.5 Study of Patients With Type 2 Diabetes
A 1-year double-blind, placebo-controlled study in type 2 diabetics (N=321) stabilized on sulfonylureas was conducted. Thirty percent of patients treated with XENICAL achieved at least a 5% or greater reduction in body weight from randomization compared to 13% of the placebo-treated patients (p<0.001). Table 11 describes the changes over 1 year of treatment with XENICAL compared to placebo, in sulfonylurea usage and dose reduction as well as in hemoglobin HbA1c, fasting glucose, and insulin.
Table 11 Mean Changes in Body Weight and Glycemic Control From Randomization Following 1-Year Treatment in Patients With Type 2 Diabetes
| XENICAL 120 mg (n=162) | Placebo (n=159) | Statistical Significance
BMI | 15.7% | 178 | 26.5% | 347 | 4.5% | 178 | 13.3% | 347
Body Weight | 11.7% | 180 | 19.0% | 348 | 3.3% | 180 | 9.5% | 348
Statistical significance based on intent-to-treat population, last observation carried forward.
a modified intent to treat – last observation carried forward (MITT-LOCF)
% patients who discontinued dose of oral sulfonylurea | 11.7% | 7.5% |
% patients who decreased dose of oral sulfonylurea | 31.5% | 21.4% |
Average reduction in sulfonylurea medication dose | -22.8% | -9.1% |
Body weight change (lbs) | -8.9 | -4.2 |
HbA1c | -0.18% | +0.28% |
Fasting glucose, mmol/L | -0.02 | +0.54 |
Fasting insulin, pmol/L | -19.68 | -18.02 | ns
In addition, XENICAL (n=162) compared to placebo (n=159) was associated with significant lowering for total cholesterol (-1.0% vs +9.0%, p≤0.05), LDL-cholesterol (-3.0% vs +10.0%, p≤0.05), LDL/HDL ratio (-0.26 vs -0.02, p≤0.05) and triglycerides (+2.54% vs +16.2%, p≤0.05), respectively. For HDL cholesterol, there was a +6.49% increase on XENICAL and +8.6% increase on placebo, p>0.05. Systolic blood pressure increased by +0.61 mm Hg on XENICAL and increased by +4.33 mm Hg on placebo, p>0.05. Diastolic blood pressure decreased by -0.47 mm Hg for XENICAL and by -0.5 mm Hg for placebo, p>0.05.
14.6 Glucose Tolerance in Obese Patients
Two-year studies that included oral glucose tolerance tests were conducted in obese patients not previously diagnosed or treated for type 2 diabetes and whose baseline oral glucose tolerance test (OGTT) status at randomization was either normal, impaired, or diabetic.
The progression from a normal OGTT at randomization to a diabetic or impaired OGTT following 2 years of treatment with XENICAL (n=251) or placebo (n=207) were compared. Following treatment with XENICAL, 0.0% and 7.2% of the patients progressed from normal to diabetic and normal to impaired, respectively, compared to 1.9% and 12.6% of the placebo treatment group, respectively.
In patients found to have an impaired OGTT at randomization, the percent of patients improving to normal or deteriorating to diabetic status following 1 and 2 years of treatment with XENICAL compared to placebo are presented. After 1 year of treatment, 45.8% of the placebo patients and 73% of the XENICAL patients had a normal oral glucose tolerance test while 10.4% of the placebo patients and 2.6% of the XENICAL patients became diabetic. After 2 years of treatment, 50% of the placebo patients and 71.7% of the XENICAL patients had a normal oral glucose tolerance test while 7.5% of placebo patients were found to be diabetic and 1.7% of XENICAL patients were found to be diabetic after treatment.
14.7 Pediatric Clinical Studies
The effects of XENICAL on body mass index (BMI) and weight loss were assessed in a 54-week multicenter, double-blind, placebo-controlled study in 539 obese adolescents (357 receiving XENICAL 120 mg three times a day, 182 receiving placebo), aged 12 to 16 years. All study participants had a baseline BMI that was 2 units greater than the US weighted mean for the 95 th percentile based on age and gender. Body mass index was the primary efficacy parameter because it takes into account changes in height and body weight, which occur in growing children.
During the study, all patients were instructed to take a multivitamin containing fat-soluble vitamins at least 2 hours before or after ingestion of XENICAL. Patients were also maintained on a well-balanced, reduced-calorie diet that was intended to provide 30% of calories from fat. In addition, all patients were placed on a behavior modification program and offered exercise counseling.
Approximately 65% of patients in each treatment group completed the study.
Following one year of treatment, BMI decreased by an average of 0.55 kg/m 2 in the XENICAL-treated patients and increased by an average of 0.31 kg/m 2 in the placebo-treated patients (p=0.001).
The percentages of patients achieving ≥5% and ≥10% reduction in BMI and body weight after 52 weeks of treatment for the intent-to-treat population are presented in Table 12 .
Table 12 Percentages of Patients with ≥5% and ≥10% Decrease in Body Mass Index and Body Weight After 1-Year Treatment (Protocol NM16189)
| Intent-to-Treat Population
≥5% Decrease | ≥10% Decrease
XENICAL | n | Placebo | n | XENICAL | n | Placebo | n
BMI | 26.5% | 347 | 15.7% | 178 | 13.3% | 347 | 4.5% | 178
Body Weight | 19.0% | 348 | 11.7% | 180 | 9.5% | 348 | 3.3% | 180